Skip to content

Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

A Principal, Prospective, Open-label Biopsy Study to Validate Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Normal Pressure Hydrocephalus (NPH) Subjects.

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01092546
Enrollment
12
Registered
2010-03-25
Start date
2010-03-31
Completion date
2011-04-30
Last updated
2013-12-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Normal Pressure Hydrocephalus

Keywords

Amyloid, Normal pressure hydrocephalus (NPH), Positron Emission Tomography (PET), Standard uptake value ratios (SUVR)

Brief summary

To determine the level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical and histochemistry estimates of amyloid levels in frontal lobe biopsy samples obtained from subjects during shunt placement for NPH.

Interventions

All subjects will receive an IV dose of \[18F\]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 MBq.

Sponsors

i3 Statprobe
CollaboratorINDUSTRY
GE Healthcare
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The subject is at least 50 years of age. * The subjects' general health is adequate to comply with study procedures. * The subject has been scheduled for a shunt placement procedure for the treatment of NPH.

Exclusion criteria

* The subject has a contraindication for MRI or PET. * The subject is pregnant or lactating. * The subject has a known or suspected hypersensitivity/allergy to \[18F\]flutemetamol or to any of the excipients. * The subject has participated in any clinical study using an investigational agent within 30 days of dosing.

Design outcomes

Primary

MeasureTime frameDescription
Standard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the Cerebellum (CER) as the Reference Region.Post flutemetamol InjectionThe level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical estimates of amyloid levels in biopsy samples obtained during shunt placement in patients who have Normal Pressure Hydrocephalus (NPH). The quantitative estimates of brain uptake of \[18F\]flutemetamol (SUVR) will be made from the analysis of PET images.

Secondary

MeasureTime frameDescription
Standard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the Pons as the Reference Region.Post flutemetamol administrationThe level of association between SUVR and the quantitative estimates (area percents) of amyloid levels for the following regions: Biopsy site and Contralateral and Composite Regions.

Countries

United States

Participant flow

Pre-assignment details

Started with 16 subjects and 4 withdrew prior to dosing leaving 12 subjects for study.

Participants by arm

ArmCount
Arm 1-Flutemetamol Injection
\[18F\]Flutemetamol : All subjects will receive an IV dose of \[18F\]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 MBq.
12
Total12

Withdrawals & dropouts

PeriodReasonFG000
Overall StudySubjects withdrawn prior to dosing4

Baseline characteristics

CharacteristicArm 1-Flutemetamol Injection
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
9 Participants
Age, Categorical
Between 18 and 65 years
3 Participants
Age, Continuous71 years
STANDARD_DEVIATION 8.1
Region of Enrollment
United States
12 participants
Sex: Female, Male
Female
5 Participants
Sex: Female, Male
Male
7 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
0 / 12
serious
Total, serious adverse events
0 / 12

Outcome results

Primary

Standard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the Cerebellum (CER) as the Reference Region.

The level of association between the quantitative estimates of brain uptake of \[18F\]flutemetamol and the quantitative immunohistochemical estimates of amyloid levels in biopsy samples obtained during shunt placement in patients who have Normal Pressure Hydrocephalus (NPH). The quantitative estimates of brain uptake of \[18F\]flutemetamol (SUVR) will be made from the analysis of PET images.

Time frame: Post flutemetamol Injection

Population: The correlation coefficient listed in the table is between SUVR-CER and the percent area of Amyloid.~Stain IHC 4G8 was used as the Standard of Truth. Standard Uptake Value Ratio (SUVR) at the site of the biopsy was based on the cerebullum (CER) as the reference region.

ArmMeasureGroupValue (NUMBER)
Arm 1-Flutemetamol InjectionStandard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the Cerebellum (CER) as the Reference Region.Biopsy Site0.64 Correlation Coefficient of the Site
Arm 1-Flutemetamol InjectionStandard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the Cerebellum (CER) as the Reference Region.Contralateral to Biopsy Site0.69 Correlation Coefficient of the Site
Arm 1-Flutemetamol InjectionStandard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the Cerebellum (CER) as the Reference Region.Composite Region0.81 Correlation Coefficient of the Site
Secondary

Standard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the Pons as the Reference Region.

The level of association between SUVR and the quantitative estimates (area percents) of amyloid levels for the following regions: Biopsy site and Contralateral and Composite Regions.

Time frame: Post flutemetamol administration

Population: The correlation coefficient listed in the table is between SUVR-Pons and the percent area of Amyloid.~Stain IHC 4G8 was used as the Standard of Truth. Standard Uptake Value Ratio (SUVR) at the site of the biopsy was based on the Pons as the reference region.

ArmMeasureGroupValue (NUMBER)
Arm 1-Flutemetamol InjectionStandard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the Pons as the Reference Region.Contralateral to Biopsy Site0.63 Correlation Coefficient of the site
Arm 1-Flutemetamol InjectionStandard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the Pons as the Reference Region.Biopsy Site0.60 Correlation Coefficient of the site
Arm 1-Flutemetamol InjectionStandard Uptake Value Ratio (SUVR) at the Site of the Biopsy Based on the Pons as the Reference Region.Composite Region0.76 Correlation Coefficient of the site

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026